KURA ONCOLOGY INC (KURA) Stock Price & Overview
NASDAQ:KURA • US50127T1097
The current stock price of KURA is 8.55 USD. Today KURA is up by 0.59%. In the past month the price increased by 3.89%. In the past year, price increased by 13.55%.
KURA Key Statistics
- Market Cap
- 744.021M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.48
- Dividend Yield
- N/A
KURA Stock Performance
KURA Stock Chart
KURA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KURA. When comparing the yearly performance of all stocks, KURA is a bad performer in the overall market: 77.13% of all stocks are doing better.
KURA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KURA. KURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
KURA Earnings
On November 4, 2025 KURA reported an EPS of -0.85 and a revenue of 20.75M. The company beat EPS expectations (2.17% surprise) and missed revenue expectations (-50.69% surprise).
KURA Forecast & Estimates
21 analysts have analysed KURA and the average price target is 32.33 USD. This implies a price increase of 278.18% is expected in the next year compared to the current price of 8.55.
For the next year, analysts expect an EPS growth of -46.97% and a revenue growth 1072.9% for KURA
KURA Groups
Sector & Classification
KURA Financial Highlights
Over the last trailing twelve months KURA reported a non-GAAP Earnings per Share(EPS) of -2.48. The EPS decreased by -5.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.4% | ||
| ROE | -89.42% | ||
| Debt/Equity | 0.02 |
KURA Ownership
KURA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.26 | 413.319B | ||
| AMGN | AMGEN INC | 16.83 | 203.007B | ||
| GILD | GILEAD SCIENCES INC | 16.62 | 183.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 120.332B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.95 | 81.051B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.86 | 42.097B | ||
| INSM | INSMED INC | N/A | 31.351B | ||
| NTRA | NATERA INC | N/A | 29.344B | ||
| BIIB | BIOGEN INC | 12.48 | 27.007B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.41 | 21.856B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.914B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.724B | ||
| MRNA | MODERNA INC | N/A | 19.468B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KURA
Company Profile
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 192 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.
Company Info
KURA ONCOLOGY INC
4930 Directors Place, Suite 500
San Diego CALIFORNIA 92130 US
CEO: Troy E. Wilson
Employees: 192
Phone: 13026587581
KURA ONCOLOGY INC / KURA FAQ
What does KURA ONCOLOGY INC do?
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 192 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.
What is the stock price of KURA ONCOLOGY INC today?
The current stock price of KURA is 8.55 USD. The price increased by 0.59% in the last trading session.
What is the dividend status of KURA ONCOLOGY INC?
KURA does not pay a dividend.
What is the ChartMill rating of KURA ONCOLOGY INC stock?
KURA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for KURA stock?
The Revenue of KURA ONCOLOGY INC (KURA) is expected to grow by 1072.9% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does KURA ONCOLOGY INC (KURA) report earnings?
KURA ONCOLOGY INC (KURA) will report earnings on 2026-03-05, before the market open.
What is the ownership structure of KURA ONCOLOGY INC (KURA)?
You can find the ownership structure of KURA ONCOLOGY INC (KURA) on the Ownership tab.